How the DEA classifies Simtriyo could determine its commercial potential in a crowded ADHD market.
FDA approves Otsuka’s ADHD drug Simtriyo, teeing up its ‘next major CNS launch’
How the DEA classifies Simtriyo could determine its commercial potential in a crowded ADHD market.
Author: Fierce Pharma
Read Original Article